INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`15112968
`
`Filing Date
`
`First Named Inventor
`
`Art Unit
`
`Examiner Name
`
`2016-07-20
`I Hamdy AHMED
`
`1618
`I Micah Paul Young
`
`Attorney Docket Number
`
`055112-5004-US
`
`31
`
`Byrd et al., "Acalabrutinib {ACP-196) in Relapsed Chronic Lymphocytic Leukemia", N Engl J Med, Vol. 374, No. 5, pp.
`323-332 (2016)
`
`32
`
`ntemational Search Report for PCT/IB2015/000645, dated August 31, 2015
`
`33
`
`v\/ritten Opinion for PCT/IB2015/000645
`
`34
`
`ntemational Search Report for PCT/IB2015/002140, dated February 28, 2016
`
`35
`
`v\/ritten Opinion for PCT/IB2015/002140
`
`If you wish to add additional non-patent literature document citation information please click the Add button I Add
`EXAMINER SIGNATURE
`
`I
`
`Examiner Signature 11
`
`11
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a
`citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
`
`I Date Considered
`
`1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO
`Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
`4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here i
`English language translation is attached.
`
`EFSWeb2.1.17
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 926 of 1432
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`15112968
`
`Filing Date
`
`First Named Inventor
`
`Art Unit
`
`Examiner Name
`
`2016-07-20
`I Hamdy AHMED
`1618
`I Micah Paul Young
`
`Attorney Docket Number
`
`055112-5004-US
`
`Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):
`
`CERTIFICATION STATEMENT
`
`That each item of information contained in the information disclosure statement was first cited in any communication
`from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
`information disclosure statement. See 37 CFR 1.97(e)(1 ).
`
`OR
`
`That no item of information contained in the information disclosure statement was cited in a communication from a
`foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
`after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
`D any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
`statement. See 37 CFR 1.97(e)(2).
`
`See attached certification statement.
`
`The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
`X A certification statement is not submitted herewith.
`
`SIGNATURE
`A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the
`form of the signature.
`
`Signature
`
`Name/Print
`
`/Deping Chai/
`
`Deping Chai
`
`Date (YYYY-MM-DD)
`
`2017-08-02
`
`Registration Number
`
`~3187
`
`This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the
`public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR
`1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed
`application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you
`require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S.
`Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND
`FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria,
`VA 22313-1450.
`
`EFSWeb2.1.17
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 927 of 1432
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the
`attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised
`that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited
`is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to
`process and/or examine your submission related to a patent application or patent. If you do not furnish the requested
`information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may
`result in termination of proceedings or abandonment of the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1.
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act
`(5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the
`Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
`
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a
`court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement
`negotiations.
`
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
`request involving an individual, to whom the record pertains, when the individual has requested assistance from the
`Member with respect to the subject matter of the record.
`
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for
`the information in order to perform a contract. Recipients of information shall be required to comply with the
`requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
`
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
`may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
`to the Patent Cooperation Treaty.
`
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of
`National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
`
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or
`his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to
`recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and
`2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this
`purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make
`determinations about individuals.
`
`8.
`
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of
`the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record
`may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in
`an application which became abandoned or in which the proceedings were terminated and which application is
`referenced by either a published application, an application open to public inspections or an issued patent.
`
`9.
`
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law
`enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.
`
`EFSWeb2.1.17
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 928 of 1432
`
`

`

`Electronic Acknowledgement Receipt
`
`EFSID:
`
`Application Number:
`
`29911545
`
`15112968
`
`International Application Number:
`
`Confirmation Number:
`
`1000
`
`Title of Invention:
`
`Methods ofTreating Chronic Lymphocytic Leukemia and Small Lymphocytic
`Leukemia Using a BTK Inhibitor
`
`First Named Inventor/Applicant Name:
`
`Hamdy Ahmed
`
`Customer Number:
`
`28977
`
`Filer:
`
`Deping Chai
`
`Filer Authorized By:
`
`Attorney Docket Number:
`
`055112-5004-US
`
`Receipt Date:
`
`Filing Date:
`
`Time Stamp:
`
`03-AUG-2017
`
`20-JUL-2016
`
`14:50:50
`
`Application Type:
`
`U.S. National Stage under 35 USC 371
`
`Payment information:
`
`Submitted with Payment
`
`I no
`
`File Listing:
`
`Document
`Number
`
`Document Description
`
`File Name
`
`File Size(Bytes}/
`Message Digest
`
`Multi
`Part /.zip
`
`Pages
`(if appl.)
`
`6224812
`
`1
`
`Foreign Reference
`
`EP2548877 Al .pdf
`
`no
`
`175
`
`d9498d8755fee3b0cfcc1eaf6451 cc337826
`3bfe
`
`Warnings:
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 929 of 1432
`
`

`

`Information:
`
`2
`
`Foreign Reference
`
`WO0l 19828.pdf
`
`no
`
`140
`
`5286865
`
`Warnings:
`
`Information:
`
`d 1 ca 1 a72cdbabaa7969632275d71 d8c7111
`aa6af
`
`14491836
`
`3
`
`Foreign Reference
`
`WO2002080926.pdf
`
`no
`
`867
`
`Warnings:
`
`Information:
`
`7c9af7c88a73106c747e299fa961 a33c7712
`7b49
`
`3182196
`
`4
`
`Foreign Reference
`
`WO2003065995.pdf
`
`no
`
`64
`
`Warnings:
`
`Information:
`
`f1 9 b3f0cece09287 34f3d 63b34a32 4eb0960
`b7cc
`
`13260279
`
`5
`
`Foreign Reference
`
`WO2005037836.pdf
`
`no
`
`286
`
`Warnings:
`
`Information:
`
`8b2a 1 bbf9c9493cacfe307e43a 7e62a5Sbf2
`975
`
`24644838
`
`6
`
`Foreign Reference
`
`WO2005097800.pdf
`
`no
`
`653
`
`Warnings:
`
`Information:
`
`f7bb553e40117fe5e2c42d710531 efff8ef61
`cdf
`
`9536500
`
`7
`
`Foreign Reference
`
`WO2007061737.pdf
`
`no
`
`238
`
`Warnings:
`
`Information:
`
`041067f0d41194f689fc9251d6ff38ecb302f
`528
`
`18409188
`
`8
`
`Foreign Reference
`
`WO2007064883.pdf
`
`no
`
`500
`
`d 64ccd Se944 b334 f4a dcc1 4f7 e9bc78Saf35
`a611
`
`Warnings:
`
`Information:
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 930 of 1432
`
`

`

`9
`
`Foreign Reference
`
`WO2007064993.pdf
`
`no
`
`114
`
`5379141
`
`Warnings:
`
`Information:
`
`58269Sdc1 edf997db3bb3091266b2e6accc
`b6e24
`
`11388149
`
`10
`
`Foreign Reference
`
`WO2007106503.pdf
`
`no
`
`295
`
`Warnings:
`
`Information:
`
`b2b38608df8d86cf66c0acc4 b3 d4802c1 3 b
`42a84
`
`8516779
`
`11
`
`Foreign Reference
`
`WO2008121742.pdf
`
`no
`
`145
`
`Warnings:
`
`Information:
`
`d9563b2873a612e273f206b92bd344c50c7
`e77f3
`
`5158763
`
`12
`
`Foreign Reference
`
`WO2009076170.pdf
`
`no
`
`57
`
`Warnings:
`
`Information:
`
`759643efcd02291453fb5dc267a5114aaeal:
`c325
`
`6132552
`
`13
`
`Foreign Reference
`
`WO2010126960.pdf
`
`no
`
`104
`
`Warnings:
`
`Information:
`
`81c30ee5c1940b27f89881 Sad5dc4921 e9a
`c6b7f
`
`6068122
`
`14
`
`Foreign Reference
`
`WO2011095556.pdf
`
`no
`
`156
`
`Warnings:
`
`Information:
`
`SdS 18c9e56974373d4e2d 1 Sded02077a 17
`eee7b1
`
`10263869
`
`15
`
`Foreign Reference
`
`WO2011119663.pdf
`
`no
`
`283
`
`992719f971 Sfa6f3b9d1 e3d5ba499c1 fe3b4
`9fbd
`
`Warnings:
`
`Information:
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 931 of 1432
`
`

`

`16
`
`Foreign Reference
`
`WO2011152351.pdf
`
`no
`
`101
`
`3215014
`
`Warnings:
`
`Information:
`
`ab8d8ec0Se82bc30c38a3b53a6fea3cfb9Sf
`4bd5
`
`13958124
`
`17
`
`Foreign Reference
`
`WO2011153514.pdf
`
`no
`
`231
`
`Warnings:
`
`Information:
`
`a89fbf95134f0c054d57bc577192146c59cf1
`012
`
`9940621
`
`18
`
`Foreign Reference
`
`WO2012158843.pdf
`
`no
`
`218
`
`Warnings:
`
`Information:
`
`c79 37 5 7b 7a81 a464 5 d 196ec5402c6d ac25 c
`9b001
`
`9892371
`
`19
`
`Foreign Reference
`
`WO2013003629.pdf
`
`no
`
`167
`
`Warnings:
`
`Information:
`
`06753ce4b3ad 13e 71621203Sd66fd47c4d7
`13141
`
`16466267
`
`20
`
`Foreign Reference
`
`WO2013010380.pdf
`
`no
`
`476
`
`Warnings:
`
`Information:
`
`aed59d36a41 56b98fe5434d76e2a816d01 E
`6d464
`
`6347095
`
`21
`
`Foreign Reference
`
`WO2013010868.pdf
`
`no
`
`114
`
`Warnings:
`
`Information:
`
`4f582c9acc5e316e6b4226f7731 a50e2db61
`9b2b
`
`3506999
`
`22
`
`Foreign Reference
`
`WO2013010869.pdf
`
`no
`
`60
`
`b212 44831 f8e8e0fa6d cc 4a02d a03 e86df78
`b3c0
`
`Warnings:
`
`Information:
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 932 of 1432
`
`

`

`23
`
`Foreign Reference
`
`WO2013059738.pdf
`
`no
`
`260
`
`17500794
`
`Warnings:
`
`Information:
`
`d71348c818d7be61 Se3972d1 ad34178e92
`2d2Sfa
`
`2733971
`
`24
`
`Foreign Reference
`
`WO2014130856.pdf
`
`no
`
`38
`
`Warnings:
`
`Information:
`
`7562ea69ca 1 af36f302fe01 e6d33b80d0fdc
`3606
`
`9871814
`
`25
`
`Foreign Reference
`
`WO2014143807.pdf
`
`no
`
`113
`
`Warnings:
`
`Information:
`
`Sf277a950f7759Se258bd1 9e2ed3ee9149c
`3aba
`
`5563687
`
`26
`
`Foreign Reference
`
`WO2014159745.pdf
`
`no
`
`103
`
`Warnings:
`
`Information:
`
`6Sc501 e3863f98732173fa5df03a93d7d826
`c46b
`
`9134893
`
`27
`
`Foreign Reference
`
`WO2014168975.pdf
`
`no
`
`121
`
`Warnings:
`
`Information:
`
`88871 f6e68868a25c5581 ad902a3cbcc97d
`ac3f9
`
`3875610
`
`28
`
`Foreign Reference
`
`WO2015018522.pdf
`
`no
`
`90
`
`Warnings:
`
`Information:
`
`b6013 2fbcf5 54 7970ab9e3 87906ca8b5 d3 c
`bSeSe
`
`5640291
`
`29
`
`Foreign Reference
`
`WO2015057992.pdf
`
`no
`
`132
`
`924118563ece2b7cb25617e1168a77ef104
`193f8
`
`Warnings:
`
`Information:
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 933 of 1432
`
`

`

`30
`
`Foreign Reference
`
`WO2015083008.pdf
`
`no
`
`241
`
`9126347
`
`Warnings:
`
`Information:
`
`a6f1 c3 944 36f3f6bd cd 2ca4 5 a90a3 73 cc9b 1
`c457
`
`1039034
`
`31
`
`Information Disclosure Statement (IDS)
`Form (SB08)
`
`0551125004US_IDS.pdf
`
`no
`
`11
`
`6b27f389c7e1c2e58599fde0315888e7c10~
`ac57
`
`Warnings:
`
`Information:
`
`Total Files Size (in bytes)
`
`275756821
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Agglications Under 35 U.S.C. 111
`If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date of the application.
`National Stage of an International Agglication under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT /DO/EO/903 indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`New International Agglication Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 181 O), a Notification of the International Application Number
`and of the International Filing Date (Form PCT/RO/1 OS) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 934 of 1432
`
`

`

`PTO/SB/OBa (03-15)
`Doc code: IDS
`Approved for use through 07/31/2016. 0MB 0651-0031
`Doc description: Information Disclosure Statement (IDS) Filed
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid 0MB control number.
`
`Application Number
`
`15112968
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Filing Date
`
`First Named Inventor
`
`Art Unit
`
`Examiner Name
`
`Attorney Docket Number
`
`2016-07-20
`I J-1amdy AHMED
`11618
`I Micah Paul Young
`I 055112-5004-US
`
`Examiner Cite
`Initial*
`No
`
`Patent Number
`
`Kind
`Code1 Issue Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`U.S.PATENTS
`
`I Remove I
`
`1
`
`~459554
`
`R008-12-02
`
`Dong et al.
`
`2
`
`~825118
`
`Ro10-11-02
`
`Honigberg et al.
`
`3
`
`~960396
`
`Ro11-06-14
`
`Honigberg et al.
`
`4
`
`a377946
`
`Ro13-02-19
`
`:;hen et al.
`
`5
`
`a658794
`
`R□ 14-02-25
`
`:leMan et al.
`
`6
`
`a290504
`
`Ro16-03-22
`
`Barf et al.
`
`If you wish to add additional U.S. Patent citation information please click the Add button.
`
`U.S.PATENT APPLICATION PUBLICATIONS
`
`I Add
`I
`I Remove I
`
`Examiner
`Initial*
`
`Cite No
`
`Publication
`Number
`
`Kind Publication
`Code1 Date
`
`Name of Patentee or Applicant
`of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`EFSWeb2.1.17
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 935 of 1432
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`15112968
`
`Filing Date
`
`First Named Inventor
`
`Art Unit
`
`Examiner Name
`
`2016-07-20
`I Hamdy AHMED
`
`1618
`I Micah Paul Young
`
`Attorney Docket Number
`
`055112-5004-US
`
`1
`
`20060084654
`
`t/006-04-20
`
`Beck et al.
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`20080076921
`
`Q008-03-27
`
`Honigberg et al.
`
`20110257203
`
`t/011-10-20
`
`Honigberg et al.
`
`20120053189
`
`t1012-03-01
`
`oury
`
`20120095026
`
`t/012-04-19
`
`Honigberg et al.
`
`20120129821
`
`t1012-05-24
`
`Honigberg et al.
`
`20120135944
`
`t/012-05-31
`
`Honigberg et al.
`
`20120165328
`
`t1012-06-28
`
`Honigberg et al.
`
`20130018032
`
`t/013-01-17
`
`:;hen et al.
`
`10
`
`20130079327
`
`t1013-03-28
`
`Yamamoto et al.
`
`11
`
`20140073593
`
`t/014-03-13
`
`:;onklin et al.
`
`EFSWeb2.1.17
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 936 of 1432
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`15112968
`
`Filing Date
`
`First Named Inventor
`
`Art Unit
`
`Examiner Name
`
`2016-07-20
`I Hamdy AHMED
`
`1618
`I Micah Paul Young
`
`Attorney Docket Number
`
`055112-5004-US
`
`12
`
`20140206681
`
`t/014-07-24
`
`Kim et al.
`
`13
`
`20140212425
`
`Q014-07-31
`
`:;hang et al.
`
`If you wish to add additional U.S. Published Application citation information please click the Add button.I Add
`I
`IRemovel
`
`FOREIGN PATENT DOCUMENTS
`
`Examiner Cite Foreign Document
`Initial*
`No Number3
`
`Country
`Code2i
`
`Kind Publication
`Code4 Date
`
`Name of Patentee or
`Applicant of cited
`Document
`
`Pages,Columns,Lines
`where Relevant
`Passages or Relevant
`Figures Appear
`
`T5
`
`1
`
`)008121742
`
`2
`
`)010126960
`
`3
`
`)011095556
`
`4
`
`)548877
`
`5
`
`)001019828
`
`6
`
`)002080926
`
`7
`
`)003065995
`
`wo
`
`WO
`
`wo
`
`EP
`
`wo
`
`WO
`
`wo
`
`EFSWeb2.1.17
`
`2008-10-09
`
`Pharmacylics, Inc.
`
`2010-11-04
`
`"ocus Pharmaceuticals,
`nc.
`
`2011-08-11
`
`Organon NV
`
`2013-01-23
`
`MSDOssB.V.
`
`2001-03-22
`
`BASF Aktiengesellschaft
`
`2002-10-17
`
`l\bbott GmbH & Co. KG
`
`2003-08-14
`
`Supergen, Inc.
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 937 of 1432
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`15112968
`
`Filing Date
`
`First Named Inventor
`
`Art Unit
`
`Examiner Name
`
`2016-07-20
`I Hamdy AHMED
`
`1618
`I Micah Paul Young
`
`Attorney Docket Number
`
`055112-5004-US
`
`8
`
`)005037836
`
`9
`
`)005097800
`
`10
`
`)007061737
`
`11
`
`)0070648
`
`12
`
`)007064993
`
`13
`
`)007106503
`
`14
`
`)009076170
`
`15
`
`)011119663
`
`16
`
`)011152351
`
`17
`
`)011153514
`
`18
`
`)012158843
`
`WO
`
`wo
`
`WO
`
`wo
`
`WO
`
`wo
`
`WO
`
`wo
`
`WO
`
`wo
`
`WO
`
`EFSWeb2.1.17
`
`2005-04-28
`
`OSI Pharmaceuticals, Inc
`
`2005-10-20
`
`OSI Pharmaceuticals, Inc
`
`2007-05-31
`
`OSI Pharmaceuticals, Inc
`
`2007-06-07
`
`Bayer Pharmaceuticals
`Corp.
`
`2001-06-07
`
`OSI Pharmaceuticals, Inc
`
`2007-09-20
`
`OSI Pharmaceuticals, Inc
`
`2009-06-18
`
`Novartis AG
`
`2011-09-29
`
`Glaxosmithkline LLC
`
`2011-12-08
`
`Ono Pharmaceutical Co.,
`"Id.
`
`2011-12-08
`
`Pharmacylics, Inc.
`
`2012-11-22
`
`Univ. California
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 938 of 1432
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`15112968
`
`Filing Date
`
`First Named Inventor
`
`Art Unit
`
`Examiner Name
`
`2016-07-20
`I Hamdy AHMED
`
`1618
`I Micah Paul Young
`
`Attorney Docket Number
`
`055112-5004-US
`
`19
`
`)013003629
`
`20
`
`)013010380
`
`21
`
`)013010868
`
`22
`
`)013010869
`
`23
`
`)013059738
`
`24
`
`)014143807
`
`25
`
`)014159745
`
`26
`
`)014159745
`
`27
`
`)014159745
`
`28
`
`)014130856
`
`29
`
`)015057992
`
`WO
`
`wo
`
`WO
`
`wo
`
`WO
`
`wo
`
`WO
`
`wo
`
`WO
`
`wo
`
`WO
`
`2013-01-03
`
`Dharmacylics, Inc.
`
`2013-01-24
`
`Merck Sharp & Dohme
`Corp.
`
`2013-01-24
`
`MSDOssB.V.
`
`2013-01-24
`
`MSDOssB.V.
`
`2013-04-25
`
`Dharmacylics, Inc.
`
`2014-09-18
`
`Stromatt, Scott
`
`2014-10-02
`
`Dharmacylics, Inc.
`
`2014-10-16
`
`Dharmacylics, Inc.
`
`2015-02-12
`
`Oncoethix SA
`
`A2
`
`2014-08-28
`
`Rothbaum et al.
`
`A1
`
`2014-04-23
`
`zumi et al.
`
`EFSWeb2.1.17
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 939 of 1432
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`15112968
`
`Filing Date
`
`First Named Inventor
`
`Art Unit
`
`Examiner Name
`
`2016-07-20
`I Hamdy AHMED
`
`1618
`I Micah Paul Young
`
`Attorney Docket Number
`
`055112-5004-US
`
`30
`
`)015083008
`
`WO
`
`A1
`
`2015-06-11
`
`l\certa Pharma B .V.
`
`If you wish to add additional Foreign Patent Document citation information please click the Add button I Add
`IRemovel
`NON-PATENT LITERATURE DOCUMENTS
`
`I
`
`Examiner Cite
`Initials* No
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item
`(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),
`publisher, city and/or country where published.
`
`T5
`
`Berge et al. "Pharmaceutical salts" 66(1) J_ Pharm. Sci. 1-19 (1977)
`
`Bingham et al., "Over one hundred solvates ofsulfathlazole" Chem. Commun. 603-04 (2001)
`
`:;aira et al., "Preparation and Crystal Characterization of a Polymorph, a Monohydrate, and an Ethyl Acetate Solvate o
`he Antifungal Fluconazole," 93(3) J_ Pharma. Sci. 601-11 (2004)
`
`Davis et al., "Chronic active B-cell-receptor signaling in diffuse large B-cell lymphoma," 463 Nature 88-92 (2010)
`
`Dhar et al., "Synthesis and SAR of p38a MAP kinase inhibitors based on heterobicyclic scaffolds," 17 Bioorg. & Med.
`:;hem. Lett. 5019-24 (2007)
`
`Gaudet et al., "A Homogeneous Fluorescence Polarization Assay Adaptable for a Range of Protein Serine/Threonine
`~nd Tyrosine Kinases," 8(2) J_ Biomol. Screening 164-75 (2003)
`
`Gennaro (ed.), Remington: The Science and Practice of Pharmacy 2oth edition (2000)
`
`Gilfillan et al., "The tyrosine kinase network regulating mast cell activation," 288 lmmun. Rev. 149-69 (2009)
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`EFSWeb2.1.17
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 940 of 1432
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`15112968
`
`Filing Date
`
`First Named Inventor
`
`Art Unit
`
`Examiner Name
`
`2016-07-20
`I Hamdy AHMED
`
`1618
`I Micah Paul Young
`
`Attorney Docket Number
`
`055112-5004-US
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`3ould "Sall selection for basic drugs" 33 lnl'I J_ Pharmaceutics 201-217 (1986)
`
`3reene & Wuls, Protective Groups in Organic Synthesis, 2d Edition (1991)
`
`Harder et al., "Gain- and Loss-of-Function Lyn Mutant Mice Define a Critical Inhibitory Role for Lyn in the Myeloid
`ineage" 15 immunity 603-15 (2001)
`
`Hartz et al., "Synthesis and Evaluation of imidazo[1,5-a]pyrazines as Corticolrophin Releasing Hormone Receptor
`igands," 12 Bioorg. & Med. Chem. Lett. 291-94 (2002)
`
`Higuchi et al. {eds.), Pro-drugs as Novel Delivery Systems. 14 A.C.S. Symposium Series (1975)
`
`'i et al., ""A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth
`actor-I receptor signaling in vitro and inhibits insulin-like growth factor-lreceptor-dependenl tumor growth in vivo,"" 6(8)
`Mol. CancerTher. 2158-67 (2007)"
`
`King et al., "Nucleofugallty effects in the pyridine promoted formation of esters from 2-subsliluled ethanesulfonyl
`~hlorides," 66 Can. J_ Chem. 1109-16 (1988)
`
`15
`
`Klinghoffer et al., "Src family kinases are required for integrin but not PDGFR signal transduction," 18(9) EMBO J_
`]459-71 (1999)
`
`im et al., "Anli-CD20 monoclonal antibodies: historical and future perspectives," 95(1) Hematological 135-43 (2010)
`
`cowell et al., "Deficiency of the Hck and Src Tyrosine Kinases Results In Extreme Levels of Extramedullary
`Hemalopoiesis," 87(5) Blood 1780-92 (1996)
`
`Mitchell et al., Synthesis of C-nucleoside isosteres of 9-(2-hydroxyethoxymethyl)guanine {acyclovir)," 21 (3) J_
`Helerocyclic Chem. 697-99 (1984)
`
`16
`
`17
`
`18
`
`19
`
`EFSWeb2.1.17
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 941 of 1432
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`15112968
`
`Filing Date
`
`First Named Inventor
`
`Art Unit
`
`Examiner Name
`
`2016-07-20
`I Hamdy AHMED
`
`1618
`I Micah Paul Young
`
`Attorney Docket Number
`
`055112-5004-US
`
`Mukalyama et al., "Synthesis and c--Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for
`reatment of acute ischemic stroke," 15 Bloom. & Med. Chem. 868-85 (2007).
`
`20
`
`Mulvihill et al., "1,3-Disubstituted-imidazo[1,5-a]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitors", 11
`Bioorg. & Med. Chem. Lett. 1091-97 (2007)
`
`Mulvihill et al., "Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-growth factor-I receptor
`IGF-IR) inhibitors", 16 Bioorg. & Med. Chem. 1359-75 (2008)
`
`:>dam et al., "Negative Regulation of immunoglobulin E-dependent Allergic Responses by Lyn Kinase," 199(11) J_ Exp
`Med. 1491-1502 (2004)
`
`Dan et al., "Discovery of Selective Irreversible Inhibitors for Bruton's Tyrosine Kinase," 2 ChemMedChem 58-61 (2007)
`
`Roby et al., "Alterations in Reproductive Function In Src Tyrosine Kinase Knockout Mice", 26 Endocrine 169-76 (2005)
`
`Roche (ed.), Bioreversible Carriers in Drug Design, Pergamon Press (1987)
`
`Shinohara et al., "Tyrosine Kinases Btk and Tee Regulate Osteoclast Differentiation by Linking RANK and ITAM
`Signals" 132 Cell 794-806 (2008)
`
`21
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`,an Tonder et al., "Preparation and Physicochemical Characterization of 5 Niclosamide Solvates and 1 Hemisolvate",
`5( 1) MPS PharmSclTech Article 12 (2004)
`
`28
`
`v\/ritten Opinion mailed 2016-08-10 relating to PCT/IB2016/053988
`
`ntemational Search Report mailed 2016-08-10 relating to PCT/182016/053988
`
`29
`
`30
`
`EFSWeb2.1.17
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 942 of 1432
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`15112968
`
`Filing Date
`
`First Named Inventor
`
`Art Unit
`
`Examiner Name
`
`2016-07-20
`I Hamdy AHMED
`
`1618
`I Micah Paul Young
`
`Attorney Docket Number
`
`055112-5004-US
`
`31
`
`Byrd et al., "Acalabrutinib {ACP-196) in Relapsed Chronic Lymphocytic Leukemia", N Engl J Med, Vol. 374, No. 5, pp.
`323-332 (2016)
`
`32
`
`ntemational Search Report for PCT/IB2015/000645, dated August 31, 2015
`
`33
`
`v\/ritten Opinion for PCT/IB2015/000645
`
`34
`
`ntemational Search Report for PCT/IB2015/002140, dated February 28, 2016
`
`35
`
`v\/ritten Opinion for PCT/IB2015/002140
`
`If you wish to add additional non-patent literature document citation information please click the Add button I Add
`EXAMINER SIGNATURE
`
`I
`
`Examiner Signature 11
`
`11
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a
`citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
`
`I Date Considered
`
`1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO
`Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
`4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here i
`English language translation is attached.
`
`EFSWeb2.1.17
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 943 of 1432
`
`

`

`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`( Not for submission under 37 CFR 1.99)
`
`Application Number
`
`15112968
`
`Filing Date
`
`First Named Inventor
`
`Art Unit
`
`Examiner Name
`
`2016-07-20
`I Hamdy AHMED
`1618
`I Micah Paul Young
`
`Attorney Docket Number
`
`055112-5004-US
`
`Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):
`
`CERTIFICATION STATEMENT
`
`That each item of information contained in the information disclosure statement was first cited in any communication
`from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
`information disclosure statement. See 37 CFR 1.97(e)(1 ).
`
`OR
`
`That no item of information contained in the information disclosure statement was cited in a communication from a
`foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
`after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
`D any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
`statement. See 37 CFR 1.97(e)(2).
`
`See attached certification statement.
`
`The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
`X A certification statement is not submitted herewith.
`
`SIGNATURE
`A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the
`form of the signature.
`
`Signature
`
`Name/Print
`
`/Deping Chai/
`
`Deping Chai
`
`Date (YYYY-MM-DD)
`
`2017-08-02
`
`Registration Number
`
`~3187
`
`This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the
`public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR
`1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed
`application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you
`require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S.
`Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND
`FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria,
`VA 22313-1450.
`
`EFSWeb2.1.17
`
`SANDOZ INC.
`
`IPR2023-00478
`
`Ex. 1004, p. 944 of 1432
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the
`attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised
`that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited
`is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to
`process and/or examine your submission related to a patent application or patent. If you do not furnish the requested
`information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may
`result in termination of proceedings or abandonment of the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1.
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act
`(5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the
`Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
`
`A record from this system of records may be disclosed, as a rout